ME01545B - Preparati s novim glikolipidnim adjuvansom - Google Patents
Preparati s novim glikolipidnim adjuvansomInfo
- Publication number
- ME01545B ME01545B MEP-2013-95A MEP9513A ME01545B ME 01545 B ME01545 B ME 01545B ME P9513 A MEP9513 A ME P9513A ME 01545 B ME01545 B ME 01545B
- Authority
- ME
- Montenegro
- Prior art keywords
- acid
- pka
- glycolipid
- weak
- sorbitan
- Prior art date
Links
- 229930186217 Glycolipid Natural products 0.000 title claims 21
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 title claims 18
- 239000002671 adjuvant Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 24
- 239000002253 acid Substances 0.000 claims 21
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims 21
- 238000002360 preparation method Methods 0.000 claims 18
- -1 L-α-aminobutyl Chemical group 0.000 claims 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 14
- 235000019441 ethanol Nutrition 0.000 claims 11
- 239000002736 nonionic surfactant Substances 0.000 claims 8
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims 7
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 claims 6
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims 6
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims 6
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims 6
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 claims 6
- 239000007983 Tris buffer Substances 0.000 claims 6
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims 6
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims 6
- 239000000872 buffer Substances 0.000 claims 5
- 150000003839 salts Chemical group 0.000 claims 5
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 claims 4
- DVLFYONBTKHTER-UHFFFAOYSA-N 3-(N-morpholino)propanesulfonic acid Chemical compound OS(=O)(=O)CCCN1CCOCC1 DVLFYONBTKHTER-UHFFFAOYSA-N 0.000 claims 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 4
- 239000004147 Sorbitan trioleate Substances 0.000 claims 4
- PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 claims 4
- 229910052739 hydrogen Inorganic materials 0.000 claims 4
- 239000001257 hydrogen Substances 0.000 claims 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims 4
- 235000011007 phosphoric acid Nutrition 0.000 claims 4
- 235000019337 sorbitan trioleate Nutrition 0.000 claims 4
- 229960000391 sorbitan trioleate Drugs 0.000 claims 4
- 229920001214 Polysorbate 60 Polymers 0.000 claims 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims 3
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims 3
- 239000001530 fumaric acid Substances 0.000 claims 3
- ODBLHEXUDAPZAU-UHFFFAOYSA-N isocitric acid Chemical compound OC(=O)C(O)C(C(O)=O)CC(O)=O ODBLHEXUDAPZAU-UHFFFAOYSA-N 0.000 claims 3
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims 3
- 239000011976 maleic acid Substances 0.000 claims 3
- 235000001968 nicotinic acid Nutrition 0.000 claims 3
- 229960003512 nicotinic acid Drugs 0.000 claims 3
- 239000011664 nicotinic acid Substances 0.000 claims 3
- 229940107700 pyruvic acid Drugs 0.000 claims 3
- 239000001384 succinic acid Substances 0.000 claims 3
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 claims 2
- SXGZJKUKBWWHRA-UHFFFAOYSA-N 2-(N-morpholiniumyl)ethanesulfonate Chemical compound [O-]S(=O)(=O)CC[NH+]1CCOCC1 SXGZJKUKBWWHRA-UHFFFAOYSA-N 0.000 claims 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims 2
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 claims 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims 2
- 241000283690 Bos taurus Species 0.000 claims 2
- 241000711895 Bovine orthopneumovirus Species 0.000 claims 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 claims 2
- 239000004471 Glycine Substances 0.000 claims 2
- 239000007995 HEPES buffer Substances 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 125000003412 L-alanyl group Chemical group [H]N([H])[C@@](C([H])([H])[H])(C(=O)[*])[H] 0.000 claims 2
- 125000000570 L-alpha-aspartyl group Chemical group [H]OC(=O)C([H])([H])[C@]([H])(N([H])[H])C(*)=O 0.000 claims 2
- 125000002059 L-arginyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C([H])([H])C([H])([H])N([H])C(=N[H])N([H])[H] 0.000 claims 2
- 125000000415 L-cysteinyl group Chemical group O=C([*])[C@@](N([H])[H])([H])C([H])([H])S[H] 0.000 claims 2
- 125000003338 L-glutaminyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C([H])([H])C(=O)N([H])[H] 0.000 claims 2
- 125000002061 L-isoleucyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])[C@](C([H])([H])[H])([H])C(C([H])([H])[H])([H])[H] 0.000 claims 2
- 125000003440 L-leucyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C(C([H])([H])[H])([H])C([H])([H])[H] 0.000 claims 2
- 125000002435 L-phenylalanyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims 2
- 125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 claims 2
- 125000002842 L-seryl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])O[H] 0.000 claims 2
- 125000000769 L-threonyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])[C@](O[H])(C([H])([H])[H])[H] 0.000 claims 2
- 125000003798 L-tyrosyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C([H])([H])C1=C([H])C([H])=C(O[H])C([H])=C1[H] 0.000 claims 2
- 125000003580 L-valyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(C([H])([H])[H])(C([H])([H])[H])[H] 0.000 claims 2
- 239000007993 MOPS buffer Substances 0.000 claims 2
- 208000002606 Paramyxoviridae Infections Diseases 0.000 claims 2
- 229920001213 Polysorbate 20 Polymers 0.000 claims 2
- IYFATESGLOUGBX-YVNJGZBMSA-N Sorbitan monopalmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O IYFATESGLOUGBX-YVNJGZBMSA-N 0.000 claims 2
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 claims 2
- 241000700605 Viruses Species 0.000 claims 2
- IJCWFDPJFXGQBN-RYNSOKOISA-N [(2R)-2-[(2R,3R,4S)-4-hydroxy-3-octadecanoyloxyoxolan-2-yl]-2-octadecanoyloxyethyl] octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCCCCCCCCCCCC IJCWFDPJFXGQBN-RYNSOKOISA-N 0.000 claims 2
- 229960001138 acetylsalicylic acid Drugs 0.000 claims 2
- 150000007513 acids Chemical class 0.000 claims 2
- 239000000427 antigen Substances 0.000 claims 2
- 102000036639 antigens Human genes 0.000 claims 2
- 108091007433 antigens Proteins 0.000 claims 2
- 239000012062 aqueous buffer Substances 0.000 claims 2
- 239000007864 aqueous solution Substances 0.000 claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 235000019253 formic acid Nutrition 0.000 claims 2
- 229940093915 gynecological organic acid Drugs 0.000 claims 2
- 150000002431 hydrogen Chemical class 0.000 claims 2
- 230000002209 hydrophobic effect Effects 0.000 claims 2
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims 2
- 239000000463 material Substances 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 150000007524 organic acids Chemical class 0.000 claims 2
- 235000005985 organic acids Nutrition 0.000 claims 2
- 235000006408 oxalic acid Nutrition 0.000 claims 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims 2
- 239000000249 polyoxyethylene sorbitan monopalmitate Substances 0.000 claims 2
- 235000010483 polyoxyethylene sorbitan monopalmitate Nutrition 0.000 claims 2
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 claims 2
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 claims 2
- 229920000053 polysorbate 80 Polymers 0.000 claims 2
- 239000011780 sodium chloride Substances 0.000 claims 2
- 239000000243 solution Substances 0.000 claims 2
- 229940035044 sorbitan monolaurate Drugs 0.000 claims 2
- 239000001593 sorbitan monooleate Substances 0.000 claims 2
- 235000011069 sorbitan monooleate Nutrition 0.000 claims 2
- 229940035049 sorbitan monooleate Drugs 0.000 claims 2
- 239000001570 sorbitan monopalmitate Substances 0.000 claims 2
- 235000011071 sorbitan monopalmitate Nutrition 0.000 claims 2
- 229940031953 sorbitan monopalmitate Drugs 0.000 claims 2
- 239000001587 sorbitan monostearate Substances 0.000 claims 2
- 235000011076 sorbitan monostearate Nutrition 0.000 claims 2
- 229940035048 sorbitan monostearate Drugs 0.000 claims 2
- 239000001589 sorbitan tristearate Substances 0.000 claims 2
- 235000011078 sorbitan tristearate Nutrition 0.000 claims 2
- 229960004129 sorbitan tristearate Drugs 0.000 claims 2
- 229960003080 taurine Drugs 0.000 claims 2
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical class [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 claims 2
- 241001529453 unidentified herpesvirus Species 0.000 claims 2
- 229960005486 vaccine Drugs 0.000 claims 2
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 claims 2
- 125000000143 2-carboxyethyl group Chemical group [H]OC(=O)C([H])([H])C([H])([H])* 0.000 claims 1
- 102100031765 3-beta-hydroxysteroid-Delta(8),Delta(7)-isomerase Human genes 0.000 claims 1
- AWQSAIIDOMEEOD-UHFFFAOYSA-N 5,5-Dimethyl-4-(3-oxobutyl)dihydro-2(3H)-furanone Chemical compound CC(=O)CCC1CC(=O)OC1(C)C AWQSAIIDOMEEOD-UHFFFAOYSA-N 0.000 claims 1
- BSYNRYMUTXBXSQ-FOQJRBATSA-N 59096-14-9 Chemical compound CC(=O)OC1=CC=CC=C1[14C](O)=O BSYNRYMUTXBXSQ-FOQJRBATSA-N 0.000 claims 1
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-N Caprylic acid Natural products CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 claims 1
- 101000866618 Homo sapiens 3-beta-hydroxysteroid-Delta(8),Delta(7)-isomerase Proteins 0.000 claims 1
- 125000002066 L-histidyl group Chemical group [H]N1C([H])=NC(C([H])([H])[C@](C(=O)[*])([H])N([H])[H])=C1[H] 0.000 claims 1
- 125000001176 L-lysyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C([H])([H])C([H])([H])C([H])([H])C(N([H])[H])([H])[H] 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 229940069428 antacid Drugs 0.000 claims 1
- 239000003159 antacid agent Substances 0.000 claims 1
- 230000001458 anti-acid effect Effects 0.000 claims 1
- 235000010323 ascorbic acid Nutrition 0.000 claims 1
- 229960005070 ascorbic acid Drugs 0.000 claims 1
- 239000011668 ascorbic acid Substances 0.000 claims 1
- GONOPSZTUGRENK-UHFFFAOYSA-N benzyl(trichloro)silane Chemical compound Cl[Si](Cl)(Cl)CC1=CC=CC=C1 GONOPSZTUGRENK-UHFFFAOYSA-N 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- KRVSOGSZCMJSLX-UHFFFAOYSA-L chromic acid Chemical class O[Cr](O)(=O)=O KRVSOGSZCMJSLX-UHFFFAOYSA-L 0.000 claims 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims 1
- 125000003745 glyceroyl group Chemical group C(C(O)CO)(=O)* 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 239000004310 lactic acid Substances 0.000 claims 1
- 235000014655 lactic acid Nutrition 0.000 claims 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 claims 1
- DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 claims 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N n-hexanoic acid Natural products CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 claims 1
- 239000008363 phosphate buffer Substances 0.000 claims 1
- 125000005547 pivalate group Chemical group 0.000 claims 1
- 229910000160 potassium phosphate Chemical class 0.000 claims 1
- 235000011009 potassium phosphates Nutrition 0.000 claims 1
- 235000019260 propionic acid Nutrition 0.000 claims 1
- 239000001488 sodium phosphate Substances 0.000 claims 1
- 229910000162 sodium phosphate Inorganic materials 0.000 claims 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical class [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
- A61K39/265—Infectious rhinotracheitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
- C07H13/12—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by acids having the group -X-C(=X)-X-, or halides thereof, in which each X means nitrogen, oxygen, sulfur, selenium or tellurium, e.g. carbonic acid, carbamic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/02—Acyclic radicals, not substituted by cyclic structures
- C07H15/12—Acyclic radicals, not substituted by cyclic structures attached to a nitrogen atom of the saccharide radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16051—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
- C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18311—Metapneumovirus, e.g. avian pneumovirus
- C12N2760/18351—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18611—Respirovirus, e.g. Bovine, human parainfluenza 1,3
- C12N2760/18634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18611—Respirovirus, e.g. Bovine, human parainfluenza 1,3
- C12N2760/18651—Methods of production or purification of viral material
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Crystallography & Structural Chemistry (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Saccharide Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Emulsifying, Dispersing, Foam-Producing Or Wetting Agents (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Claims (17)
1. Pripravak, naznačen time što sadrži: a) glikolipid Formule I; gdje je Formula I gdje R i R su neovisno vodik, ili zasićeni alkilni radikal s do 20 atoma ugljika; Xje-CH2-,-O-ili-NH-; R\ R4 i R5 su neovisno vodik, -SO42 , -PO42 , -COC1-10alkil; R6 je L-alanil, L-a-aminobutil, L-arginil, L-asparginil, L-aspartil, L-cisteinil, L-glutamil, L-glicil, L-hislidil, L-hidroksiprolil, L-izoleucil, L-leucil, L-lizil, L-metionil, L-omitinil, L-fenilalanil, L-prolil, L-seril, L -treonil, L-tirozil, L-triptofanil, te L-valil ili njihovi D-izomeri; u obliku soli, gdje se solni oblik dobiva iz slabe kiseline; b)alkohol, gdje je alkohol HO-C1-3a]kil; c)slaba kiselina, gdje je slaba kiselina 1)u količini od 1,25 do 5,0 puta većoj od količine glikolipida, u molarnim ekvivalentima glikolipida,i 2)bilo koja kiselina s vrijednošću pKa (-log Ka) između 1,0 i 9,5, uz upotrebu standardnih tablica ilivrijednosti; d) neionski surfaktant, gdje je neionski surfaktant sredstvo koje smanjuje površinsku napetost materijalau kojem je otopljeno i ima komponentu koja je hidrofobna, te drugu komponentu koja je hidrofilna.
2. Pripravak u skladu s patentnim zahtjevom 1, naznačen time Stoje glikolipid spoj Formule II(a) a slabu kiselinu se bira između jedne ili bilo koje kombinacije sljedećih slabih kiselina: octene kiseline, H(C2H3O2) (pKa 4,76); askorbinske kiseline (1), H2(C6H6O6) (pKa 4,10); acetilsalicilne kiseline, H8(C9O4), (pK3 3,5); butanske kiseline H(C4H7O2) (pKa 4,83); ugljične kiseline, oblik 1, H2CO3, (pKa 4,83); kromne kiseline, oblik 2, HCrO4-, (pKa 6,49); limunske kiseline, oblik 1, H3(C6H5O7), (pKa 3,14); limunske kiseline, oblik 2, (H2C6O7)-, (pKa 4,77); limunske kiseline, oblik 3, (HC6H5O7)2-, (pKa 6,39); mravlje kiseline, H(CHO2), (pKa 3,75); fumarne kiseline, H4(C4O4) (pKa 3,03); heptanske kiseline, H(C7H|3O2), (pKa 4,89); heksanske kiseline, H(C6HnO2), (pKa 4,84); fluorovodučne kiseline, HF, (pKa 3,20); izocitrata, H8(C6O7) (pKa 3,29); mliječne kiseline, H(C3H5O3), (pKa 3,08); maleinske kiseline, H4(C4O4) (pKa 1,83); nikotinske kiseline, H5(C6NO2) (pKa 3,39); oksalne kiseline, oblik 1, H2(C2O4), (pKa 1,23); oksalna kiselina, oblik 2, (HC2O4); (pKa 4,19); pentanske kiseline, H(C5H9O2), (pKa 4,84); fosforne kiseline, oblik 1, H3PO4, (pKa 2,16); propanske kiseline, H(C3H5O2), (pKa 4,86); pirogrožđane kiseline, H4(C3O3) (pKa 2,39); te jantarne kiseline H6(C4O4) (pATa 4,19).
3. Pripravak u skladu s patentnim zahtjevom 2, naznačen time stoje glikolipid spoj Formule II(b) a slabu kiselinu se bira između jedne ili bilo koje kombinacije sljedećih slabih kiselina: octene kiseline; acetilsalicilne kiseline; limunske kiseline; mravlje kiseline; fumarne kiseline; fluorovodične kiseline; izocitrata; maleinske kiseline; nikotinske kiseline; fosforne kiseline; pirogrožđane kiseline; te jantarne kiseline.
4. Pripravak u skladu s patentnim zahtjevom 3, naznačen time stoje glikolipid iV-(2-deoksi-2-L-leucilamino-/J-D-glukopiranozil)-N-oktadecil-dodekanamid-acetat, sa strukturom Formule III: a slaba kiselina je octena kiselina.
5. Pripravak u skladu s patentnim zahtjevom 2, naznačen time što se slabu kiselinu bira iz skupine koju čine:octena kiselina; acetilsalicilna kiselina; limunska kiselina, oblik 1; limunska kiselina, oblik 2; limunska kiselina, oblik 3; mravlja kiselina; fumarna kiselina; fluorovodična kiselina; izocitrat; maleinska kiselina; nikotinska kiselina; fosforna kiselina, oblik 1; pirogroždana kiselina; te jantarna kiselina.
6. Pripravak u skladu s bilo kojim od patentnih zahtjeva 1-5, naznačen time što je navedena slaba kiselina u količini većoj od molamog ekvivalenta glikolipida kao što slijedi: a) 1,25 puta većoj, b) 2,0 puta većoj, c) 2,5 puta većoj, d) 2,7 puta većoj, e) 3,0 puta većoj, f) 5,0 puta većoj od molarno ekvivalente količine glikolipida.
7.Pripravak u skladu s bilo kojim od patentnih zahtjeva 1-6, naznačen time stoje alkohol etil-alkohol.
8. Pripravak u skladu s bilo kojim od patentnih zahtjeva 1-7, naznačen time što se navedeni neionski surfaktant bira između bilo kojeg ili kombinacije iz skupine koju čine: sorbitan-monolaurat, sorbitan-monopalmitat,sorbitan-monostearat, sorbitan-tristearat, sorbitan-monooleat, sorbitan-trioleat, polioksietilensorbitan-monolaurat, polioksietilensorbitan-monopalmitat, polioksietilensorbitan-monostearat, polioksietilensorbitan-monooleat, polioksietilensorbitan-trioleat, te drugi sorbitani i polioksietilen-sorbitani koje se običnoupotrebljava u cjepivima.
9.Pripravak u skladu s patentnim zahtjevom 1, naznačen time stoje slaba kiselina octena kiselina, te stoje octena kiselina u količini 2,0 puta većoj od molarno ekvivalente količine glikolipida.
10. Pripravak u skladu s patentnim zahtjevom 1, naznačen time što slaba kiselina ima vrijednost pK3 (-log Ka) između 1,23 i 6,49, uz upotrebu standardnih tablica ili vrijednosti.
11.Pripravak, naznačen time što sadrži: a) glikolipid Formule I; gdje je Formula I gdje R1 i R2 su neovisno vodik, ili zasićeni alkilni radikal s do 20 atoma ugljika; Xje-CH2-, -O-ili-NH-; R3,R4 i R5 su neovisno vodik, -SO42-, -PO42, -COCMOalkil; R6je L-alanil, L-a-aminobutil, L-arginil, L-asparginil, L-aspartil, L-cisteinil, L-glutamil, L-glicil, L-histidil, L-hidroksiprolil, L-izoleucil, L-leucil, L-lizil, L-metionil, L-ornitinil, L-fenilalanil, L-prolil, L-seril, L-treonil, L-tirozil, L-triptofanil, te L-valil ili njihovi D-izomeri; u obliku soli, gdje se solni oblik dobiva iz slabe kiseline; b)alkohol, gdje je alkohol HO-C,.3alkil; c)slabu kiselinu, gdje je slaba kiselina 1)u količini od 1,25 do 5,0 puta većoj od količine glikolipida, u molarnim ekvivalentima glikolipida,i 2)bilo koja kiselina s vrijednošću pKa (-log Ka) između otprilike 1,0 i otprilike 9,5, uz upotrebustandardnih tablica ili vrijednosti; d)neionski surfaktant, gdje je neionski surfaktant sredstvo koje smanjuje površinsku napetost materijalau kojem je otopljeno i ima komponentu koja je hidrofobna, te drugu komponentu koja je hidrofilna; i e)vodeni pufer, gdje je pogodni pufer pogodan za upotrebu u cjepivu i može održavati pH drugihsastojaka u rasponu pH od 6 do 8, uz uvjet da se upotrijebi najviše 50 mM NaCl.
12. Pripravak u skladu s patentnim zahtjevom 11, naznačen time što se pH otopine podesi do relativno konstantnog pH u vodenoj otopini od između 6 i 7, a pufer se bira iz skupine koju čine fosfatni puferi koje čine bilo koja od ili i monobazične i dibazične soli natrijevog fosfata i/ili kalijevog fosfata, u istim ili različitim udjelima.
13.Pripravak u skladu s patentnim zahtjevom 11, naznačen time što se navedeni pufer bira iz skupine koju čine: a)2-(N-morfolino)etansufonska kiselina (poznata i kao MES); b)3-(N-morfolino)propansulfonska kiselina (poznata i kao MOPS); c)n-[tris(hidroksimetil)]-2-aminoetansulfonska kiselina (poznata i kao TES); d)4-(2-hidroksietil)piperazin-l-etansulfonska kiselina (poznata i kao HEPES); i e)[tris(hidroksimetil)metil]glicin (poznat i kao TRIS);ili bilo koja njihova kombinacija.
14. Pripravak u skladu s bilo kojim od patentnih zahtjeva 1-13, naznačen time što dodatno sadrži antigen kojeg se bira iz skupine, ili bilo koje njihove kombinacije, koju čine modificirani živi goveđi herpes virus, modificirani živi goveđi respiratorni sincicjski virus, te modificirani živi virus parainfluence 3.
15.Pripravak, naznačen time što sadrži: a) N-(2-deoksi-2-L-leucilamino-β-D-glukopiranozil)-N-oktadecildodekanamid-acetat, sa strukturom Formule III: b) etanol; c)octenu kiselinu, gdje je octena kiselina u količini od 1,25 do 5,0 puta većoj od količine glikolipida, umolarnim ekvivalentima glikolipida; d)neionski surfaktant, kojeg se bira između sorbitan-monolaurata, sorbitan-monopalmitata, sorbitan-monostearata, sorbitan-tristearata, sorbitan-monooleata, sorbitan-trioleata, polioksietilensorbitan-monolaurata, polioksietilensorbitan-monopalmitata, polioksietilensorbitan-monostearata,polioksietilensorbitan-monooleata, polioksietilensorbitan-trioleata; e)vodeni pufer, gdje se pH otopine podesi do relativno konstantnog pH u puferiranoj vodenoj otopini odizmeđu 6 i 7, a pufer se bira iz skupine koju čine: a)2-(N-morfolino)etansufonska kiselina (poznata i kao MES); b)3-(N-morfolino)propansulfonska kiselina (poznata i kao MOPS); c)n-[tris(hidroksimetil)]-2-aminoetansulfonska kiselina (poznata i kao TES); d)4-(2-hidroksietiI)piperazin-l-etansulfonska kiselina (poznata i kao HEPES); i e)[tris(hidroksimetil)metil]glicin (poznat i kao TRIS);ili bilo koja njihova kombinacija, uz uvjet da se upotrijebi najviše 15 mM NaCl; i f) antigen, koji je uglavnom modificirani živi goveđi herpes virus, modificirani živi goveđi respiratorni sincicjski virus, te modificirani živi virus parainfluence 3.
16. Postupak priprave pripravka, naznačen time što se sastoji u miješanju zajedno sljedećeg: a)glikolipida Formule I; b)alkohola, gdje je alkohol HO-C1-3alkil; c)slabe organske kiseline, gdje je slaba kiselina 1)u količini od 1,25 do 5,0 puta većoj od količine glikolipida, u molarnim ekvivalentima glikolipida;i 2)bilo koja kiselina s vrijednošću pKa (-log Ka) između 1 i 9,5, uz upotrebu standardnih tablica ilivrijednosti; i d) neionskog surfaktanta.
17. Postupak priprave pripravka, naznačen time što se sastoji u miješanju zajedno sljedećeg: a)glikolipida Formule I; b)alkohola, gdje je alkohol HO-C1-3alkil; c)slabe organske kiseline, gdje je slaba kiselina 1)u količini od 1,25 do 5,0 puta većoj od količine glikolipida, u molarnim ekvivalentima glikolipida;i 2)bilo koja kiselina s vrijednošću pKa (-log Ka) između 0,7 i 9,5, uz upotrebu standardnih tablica ilivrijednosti; d)neionskog surfaktanta; gdje se zatim doda; e)pogodni pufer.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US76227906P | 2006-01-26 | 2006-01-26 | |
| US81498406P | 2006-06-20 | 2006-06-20 | |
| EP07705530.9A EP1991266B1 (en) | 2006-01-26 | 2007-01-15 | Novel glycolipid adjuvant compositions |
| PCT/IB2007/000258 WO2007085962A2 (en) | 2006-01-26 | 2007-01-15 | Novel glycolipid adjuvant compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ME01545B true ME01545B (me) | 2014-04-20 |
Family
ID=38309580
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2008-45A ME00045B (me) | 2006-01-26 | 2007-01-15 | Nove kompozicije glikolipidnog adjuvansa |
| MEP-2013-95A ME01545B (me) | 2006-01-26 | 2007-01-15 | Preparati s novim glikolipidnim adjuvansom |
| MEP-45/08A MEP4508A (en) | 2006-01-26 | 2007-01-15 | Novel glycolipid adjuvant compositions |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2008-45A ME00045B (me) | 2006-01-26 | 2007-01-15 | Nove kompozicije glikolipidnog adjuvansa |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-45/08A MEP4508A (en) | 2006-01-26 | 2007-01-15 | Novel glycolipid adjuvant compositions |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US8460679B2 (me) |
| EP (2) | EP2481423A1 (me) |
| JP (1) | JP5538725B2 (me) |
| KR (2) | KR20110140140A (me) |
| AR (1) | AR059192A1 (me) |
| AU (1) | AU2007209104B2 (me) |
| BR (1) | BRPI0706709B8 (me) |
| CA (1) | CA2634888C (me) |
| CY (1) | CY1114310T1 (me) |
| DK (1) | DK1991266T3 (me) |
| ES (1) | ES2425576T3 (me) |
| ME (3) | ME00045B (me) |
| NO (1) | NO341463B1 (me) |
| NZ (1) | NZ569375A (me) |
| PL (1) | PL1991266T3 (me) |
| PT (1) | PT1991266E (me) |
| RS (2) | RS20080318A (me) |
| RU (1) | RU2392965C2 (me) |
| TW (1) | TWI372631B (me) |
| WO (1) | WO2007085962A2 (me) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2040745B1 (en) * | 2006-06-28 | 2012-12-05 | Statens Serum Institut | Expanding the t cell repertoire to include subdominant epitopes by vaccination with antigens delivered as protein fragments or peptide cocktails |
| WO2009156960A2 (en) * | 2008-06-27 | 2009-12-30 | Pfizer Inc. | Novel adjuvant compositions |
| BRPI0920800A2 (pt) | 2008-10-03 | 2020-08-11 | Novartis Ag | vírus da herpes bovina-1, composição, método para produzir uma resposta imunológica em um hospedeiro, e, uso de vírus da herpes bovina-1. |
| ES2743465T3 (es) * | 2013-03-15 | 2020-02-19 | Glaxosmithkline Biologicals Sa | Composición que contiene derivados fosfato de aminoalquil glucosaminida tamponados y su uso para potenciar una respuesta inmunitaria |
| UA121200C2 (uk) | 2013-09-19 | 2020-04-27 | Зоетіс Сервісіз Ллс | Ад'ювант на основі олії |
| US11318200B2 (en) | 2013-11-26 | 2022-05-03 | Zoetis Services Llc | Methods and compositions for induction of immune response |
| EP4248992A3 (en) | 2015-01-16 | 2023-12-27 | Zoetis Services LLC | Foot-and-mouth disease vaccine |
| KR102085968B1 (ko) * | 2015-07-20 | 2020-03-06 | 조에티스 서비시즈 엘엘씨 | 리포솜 보조제 조성물 |
| GB201703529D0 (en) | 2017-03-06 | 2017-04-19 | Cambridge Entpr Ltd | Vaccine composition |
| CN110713520B (zh) * | 2019-11-06 | 2021-01-01 | 中国石油天然气股份有限公司 | 油酰基氨基酸-γ-L-谷氨酰-L-半胱氨酰-甘氨酸多肽及其制备与应用 |
| TWI884296B (zh) | 2020-08-11 | 2025-05-21 | 美商碩騰服務公司 | 抗冠狀病毒疫苗 |
| WO2022072431A1 (en) | 2020-09-30 | 2022-04-07 | Zoetis Services Llc | Novel pasteurella multocida strains and vaccines having hyac and nanp deletions |
| CN121360223A (zh) | 2024-07-19 | 2026-01-20 | 硕腾服务有限责任公司 | 流感疫苗 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4291019A (en) * | 1979-07-09 | 1981-09-22 | Iowa State University Research Foundation, Inc. | Vaccine for infectious bovine rhinotracheitis |
| DE3213650A1 (de) | 1982-04-14 | 1983-10-27 | Bayer Ag, 5090 Leverkusen | N-glycosylierte carbonsaeureamid-derivate, verfahren zu ihrer herstellung sowie ihre verwendung zur beeinflussung der koerpereigenen abwehr |
| DE3403495A1 (de) | 1983-11-23 | 1985-05-30 | Bayer Ag, 5090 Leverkusen | Phosphorylierte glycosylamide, -harnstoffe, -carbamate und -thiocarbamate, verfahren zu ihrer herstellung sowie ihre verwendung |
| DE3346623A1 (de) | 1983-12-14 | 1985-07-04 | Bayer Ag, 5090 Leverkusen | N-glycosylierte harnstoffe, carbamate und thiocarbamate, verfahren zu ihrer herstellung sowie ihre verwendung |
| DE3521994A1 (de) * | 1985-06-20 | 1987-01-02 | Bayer Ag | N-(2-aminoacylamido-2-desoxy-hexosyl)-amide-, -carbamate und -harnstoffe, verfahren zu ihrer herstellung sowie ihre verwendung in arzneimitteln |
| NZ232740A (en) * | 1989-04-20 | 1992-06-25 | Riker Laboratories Inc | Solution for parenteral administration comprising a 1h-imidazo(4,5-c) quinolin-4-amine derivative, an acid and a tonicity adjuster |
| US6764682B1 (en) * | 1994-06-16 | 2004-07-20 | Aventis Pasteur Limited | Adjuvant compositions containing more than one adjuvant |
| US5718904A (en) | 1995-06-02 | 1998-02-17 | American Home Products Corporation | Adjuvants for viral vaccines |
| US6290971B1 (en) | 1995-06-15 | 2001-09-18 | Aventis Pasteur Limited | Adjuvant compositions comprising a mineral salt and another immunostimulating compound |
| FI109332B (fi) * | 1998-12-17 | 2002-07-15 | Orion Yhtymae Oyj | Toremifeenin liukoisia koostumuksia |
| MXPA03002890A (es) * | 2000-10-02 | 2004-12-03 | Glaxosmithkline Biolog Sa | Preparacion de virus con envolvente dividido. |
-
2007
- 2007-01-15 ES ES07705530T patent/ES2425576T3/es active Active
- 2007-01-15 ME MEP-2008-45A patent/ME00045B/me unknown
- 2007-01-15 BR BRPI0706709A patent/BRPI0706709B8/pt active IP Right Grant
- 2007-01-15 CA CA2634888A patent/CA2634888C/en active Active
- 2007-01-15 RS RSP-2008/0318A patent/RS20080318A/sr unknown
- 2007-01-15 NZ NZ569375A patent/NZ569375A/en unknown
- 2007-01-15 AU AU2007209104A patent/AU2007209104B2/en active Active
- 2007-01-15 KR KR1020117028574A patent/KR20110140140A/ko not_active Ceased
- 2007-01-15 ME MEP-2013-95A patent/ME01545B/me unknown
- 2007-01-15 EP EP12165409A patent/EP2481423A1/en not_active Withdrawn
- 2007-01-15 EP EP07705530.9A patent/EP1991266B1/en active Active
- 2007-01-15 ME MEP-45/08A patent/MEP4508A/xx unknown
- 2007-01-15 DK DK07705530.9T patent/DK1991266T3/da active
- 2007-01-15 PT PT77055309T patent/PT1991266E/pt unknown
- 2007-01-15 PL PL07705530T patent/PL1991266T3/pl unknown
- 2007-01-15 RS RS20130372A patent/RS52930B/sr unknown
- 2007-01-15 RU RU2008129203/15A patent/RU2392965C2/ru active
- 2007-01-15 JP JP2008551904A patent/JP5538725B2/ja active Active
- 2007-01-15 WO PCT/IB2007/000258 patent/WO2007085962A2/en not_active Ceased
- 2007-01-15 KR KR1020087018207A patent/KR101202553B1/ko active Active
- 2007-01-25 TW TW096102865A patent/TWI372631B/zh active
- 2007-01-25 AR ARP070100334A patent/AR059192A1/es not_active Application Discontinuation
- 2007-01-26 US US11/698,335 patent/US8460679B2/en active Active
-
2008
- 2008-08-04 NO NO20083405A patent/NO341463B1/no unknown
-
2013
- 2013-09-03 CY CY20131100756T patent/CY1114310T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2008129203A (ru) | Новые гликолипидные адъювантные композиции | |
| CN101378655B (zh) | 稳定的浓缩除草组合物 | |
| RU2019142130A (ru) | Композиции, содержащие триптановые соединения | |
| RU2012111427A (ru) | Водные композиции концентратов, содержащие сафлуфенацил и глифосфат | |
| CA2591052A1 (en) | Herbicidal composition comprising an aminophosphate or aminophosphonate salt and a betaine | |
| EA201070099A1 (ru) | Алкоксилированные асимметричные алкиламинные поверхностно-активные вещества в качестве адъювантов | |
| RU2638947C1 (ru) | Новое соединение метилового эфира 2-бензимидазолилкарбаминовой кислоты с модификациями мочевины, обладающее фунгицидными свойствами, и фунгицидное средство на его основе | |
| ATE359309T1 (de) | Wasserlösliche aspartate | |
| EP2296477B1 (en) | Herbicide formulation | |
| RU2010101930A (ru) | Производные нистатина и их применение в качестве противогрипковых агентов | |
| US12144343B2 (en) | Stable high-load herbicidal compositions comprising mixed amine oxides | |
| AR105393A1 (es) | Composiciones adyuvantes liposómicas | |
| TH105083A (th) | องค์ประกอบสารเสริมไกลโคไลพิดชนิดใหม่ | |
| TH76917B (th) | องค์ประกอบสารเสริมไกลโคไลพิดชนิดใหม่ | |
| US20090264664A1 (en) | Preparation for external application comprising salt of mast cell degranulation inhibitor having carboxyl group with organic amine | |
| CN101374551B (zh) | 新的糖脂佐剂组合物 | |
| US20200337953A1 (en) | Emulsified composition | |
| US9668470B2 (en) | Method for producing a liquid emulsifiable formulation comprising a pyripyropene pesticide | |
| CN1830256A (zh) | 用于基于n－膦酰甲基甘氨酸及其盐的除草剂配方中的高性能助剂组合物 | |
| EP2448405B1 (en) | Aqueous herbicide concentrate | |
| CA2944034A1 (en) | Alkanolamine sulfate water conditioners | |
| EP3303248B1 (en) | Fatty alcohol aqueous suspension-based anti-filming surface admixture | |
| JP2001138656A (ja) | 平版印刷用濃縮湿し水組成物 | |
| JP2024525239A5 (me) | ||
| JP2009013017A (ja) | コンクリート用起泡剤 |